Simplex Trading LLC Acquires 22,932 Shares of Prelude Therapeutics Incorporated $PRLD

Simplex Trading LLC grew its holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 121.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,846 shares of the company’s stock after acquiring an additional 22,932 shares during the quarter. Simplex Trading LLC owned 0.10% of Prelude Therapeutics worth $32,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PRLD. Boxer Capital Management LLC bought a new stake in shares of Prelude Therapeutics in the fourth quarter valued at approximately $2,178,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Prelude Therapeutics by 280.9% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 666,574 shares of the company’s stock valued at $850,000 after acquiring an additional 491,595 shares during the period. Renaissance Technologies LLC boosted its position in shares of Prelude Therapeutics by 222.2% in the fourth quarter. Renaissance Technologies LLC now owns 634,500 shares of the company’s stock valued at $809,000 after acquiring an additional 437,600 shares during the period. Millennium Management LLC boosted its position in shares of Prelude Therapeutics by 188.2% in the fourth quarter. Millennium Management LLC now owns 462,555 shares of the company’s stock valued at $590,000 after acquiring an additional 302,031 shares during the period. Finally, Two Sigma Advisers LP boosted its position in shares of Prelude Therapeutics by 526.3% in the fourth quarter. Two Sigma Advisers LP now owns 300,000 shares of the company’s stock valued at $382,000 after acquiring an additional 252,100 shares during the period. 79.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on PRLD. JMP Securities reduced their price objective on Prelude Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Monday, August 18th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Prelude Therapeutics in a research report on Monday, May 5th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Prelude Therapeutics has an average rating of “Buy” and a consensus target price of $4.00.

Prelude Therapeutics Price Performance

Shares of PRLD stock opened at $1.24 on Monday. The stock has a market cap of $70.18 million, a P/E ratio of -0.76 and a beta of 1.22. Prelude Therapeutics Incorporated has a one year low of $0.6101 and a one year high of $5.9450. The stock has a fifty day moving average price of $0.87 and a 200 day moving average price of $0.85.

Prelude Therapeutics (NASDAQ:PRLD) last issued its earnings results on Thursday, August 14th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04. Equities research analysts anticipate that Prelude Therapeutics Incorporated will post -1.81 EPS for the current year.

Prelude Therapeutics Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.